CA2536047A1 — Spray-dried amorphous bibn 4096 method for production and use thereof as inhalant
Assigned to Boehringer Ingelheim International GmbH · Expires 2005-03-03 · 21y expired
What this patent protects
The invention relates to the CGRP antagonist 1-[N?2¿-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A), or the physiologically-acceptable salts thereof, which are stable in the amorphous state unde…
USPTO Abstract
The invention relates to the CGRP antagonist 1-[N?2¿-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A), or the physiologically-acceptable salts thereof, which are stable in the amorphous state under normal conditions (T < 50 ·C, relative humidity < 75%) in the form of microparticles, methods for production of microparticles of said substances and the use of said microparticles for the production of a medicament in the application form of a powder inhalant for pulmonary and nasal inhalation, in particular, for the production of a medicament for the treatment of headaches, migraines and cluster headaches.
Drugs covered by this patent
- Remodulin (TREPROSTINIL) · United Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.